Active ingredientTrofinetideCat. No. P-T224-001CAS 853400-76-7Family · Pharmaceutical analytical standards
Trofinetide
A synthetic analogue of the tripeptide glycine-proline-glutamate, which the brain cuts from the growth factor IGF-1; approved in the United States in March 2023, it is the first authorised treatment for Rett syndrome, from two years of age. This family brings together the active ingredient and other impurities.
Did you know?Before reaching Rett syndrome it had been studied as a possible treatment for stroke; it also gave positive results in a phase II trial in fragile X syndrome.
Go to the active ingredient →Active ingredientTrofinetideCat. No. P-T224-001CAS 853400-76-7
ImpurityTrofinetide Impurity 1 HydrochlorideCat. No. P-T224-002CAS 1286768-32-8
ImpurityTrofinetide Impurity 2Cat. No. P-T224-005CAS 146844-02-2No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.